Atara Biotherapeutics/$ATRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Atara Biotherapeutics
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Ticker
$ATRA
Sector
Primary listing
Employees
14
Headquarters
Website
ATRA Metrics
BasicAdvanced
$35M
1.68
$2.57
-0.40
-
Price and volume
Market cap
$35M
Beta
-0.4
52-week high
$19.15
52-week low
$3.92
Average daily volume
376K
Financial strength
Current ratio
0.818
Quick ratio
0.652
Long term debt to equity
-24.277
Total debt to equity
-26.947
Interest coverage (TTM)
13.05%
Profitability
EBITDA (TTM)
51.587
Gross margin (TTM)
61.79%
Net profit margin (TTM)
27.07%
Operating margin (TTM)
40.96%
Effective tax rate (TTM)
0.09%
Revenue per employee (TTM)
$8,630,000
Management effectiveness
Return on assets (TTM)
47.81%
Return on equity (TTM)
-48.15%
Valuation
Price to earnings (TTM)
1.681
Price to revenue (TTM)
0.449
Price to book
-0.82
Price to tangible book (TTM)
-0.82
Price to free cash flow (TTM)
-1.064
Free cash flow yield (TTM)
-94.00%
Free cash flow per share (TTM)
-4.061
Growth
Revenue change (TTM)
-6.33%
Earnings per share change (TTM)
-122.52%
3-year revenue growth (CAGR)
23.85%
3-year earnings per share growth (CAGR)
-64.19%
10-year earnings per share growth (CAGR)
-26.51%
What the Analysts think about ATRA
Analyst ratings (Buy, Hold, Sell) for Atara Biotherapeutics stock.
ATRA Financial Performance
Revenues and expenses
ATRA Earnings Performance
Company profitability
ATRA News
AllArticlesVideos
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
Newsfile Corp·9 hours ago
ATRA EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
Newsfile Corp·12 hours ago
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
Newsfile Corp·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Atara Biotherapeutics stock?
Atara Biotherapeutics (ATRA) has a market cap of $35M as of March 31, 2026.
What is the P/E ratio for Atara Biotherapeutics stock?
The price to earnings (P/E) ratio for Atara Biotherapeutics (ATRA) stock is 1.68 as of March 31, 2026.
Does Atara Biotherapeutics stock pay dividends?
No, Atara Biotherapeutics (ATRA) stock does not pay dividends to its shareholders as of March 31, 2026.
When is the next Atara Biotherapeutics dividend payment date?
Atara Biotherapeutics (ATRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Atara Biotherapeutics?
Atara Biotherapeutics (ATRA) has a beta rating of -0.4. This means that it has an inverse relation to market volatility.